ClinVar Miner

Submissions for variant NM_000090.3(COL3A1):c.962G>A (p.Gly321Asp) (rs587779588)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000435885 SCV000521082 likely pathogenic not provided 2016-06-23 criteria provided, single submitter clinical testing The G321D likely pathogenic variant in the COL3A1 gene has been reported in association with EDS type IV (Pepinet al., 2014). In a cohort of 572 EDS type IV index patients harboring an underlying heterozygous COL3A1 variant, G321D was identified in one individual (Pepin et al, 2014). Moreover, the G321D variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G321D variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In addition, this substitution occurs at a position that is conserved across species. Consequently, in silico analysis predicts this variant is probably damaging to the protein structure/function. The G321D variant affects a Glycine residue in a Gly-X-Y motif in the triple helical region of the COL3A1 gene, where the majority of pathogenic missense variants occur (Stenson et al., 2014; Symoens et al., 2012). Furthermore, Pepin et al. (2014) reported that EDS type IV patients harboring missense variants in which Aspartic acid is substituted for Glycine within the triple helical region of COL3A1 have a decreased life expectancy compared to individuals with COL3A1 null variants (Hazard Ratio = 5.3). Finally, a missense variant in the same residue (G321V) has been reported in the Human Gene Mutation Database in association with EDS type IV (Stenson et al., 2014); however, the pathogenicity of this variant has not been definitively determined. Therefore, this variant is likely pathogenic. In order to definitively determine its clinical significance, additional data is required.
Invitae RCV000087628 SCV000756056 pathogenic Ehlers-Danlos syndrome, type 4 2017-11-13 criteria provided, single submitter clinical testing This sequence change replaces glycine with aspartic acid at codon 321 of the COL3A1 protein (p.Gly321Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. This variant is not present in population databases (ExAC no frequency). This variant has been reported in an individual affected with vascular Ehlers–Danlos syndrome (PMID: 24922459). Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic.
Collagen Diagnostic Laboratory,University of Washington RCV000087628 SCV000120519 pathogenic Ehlers-Danlos syndrome, type 4 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.